Translational medicine

• Verfasst von: Kallenbach, Klaus [VerfasserIn]
• Verfasst von: Remes, Anca [VerfasserIn]
• Verfasst von: Müller, Oliver J. [VerfasserIn]
• Verfasst von: Arif, Rawa [VerfasserIn]
• Verfasst von: Zaradzki, Marcin [VerfasserIn]
• Verfasst von: Wagner, Andreas H. [VerfasserIn]
• Titel: Translational medicine
• Titelzusatz: towards gene therapy of marfan syndrome
• Verf.angabe: Klaus Kallenbach, Anca Remes, Oliver J. Müller, Rawa Arif, Marcin Zaradzki and Andreas H. Wagner
• E-Jahr: 2022
• Jahr: 6 July 2022
• Umfang: 11 S.
• Fussnoten: Gesehen am 05.09.2022
• Titel Quelle: Enthalten in: Journal of Clinical Medicine
• Ort Quelle: Basel : MDPI, 2012
• Jahr Quelle: 2022
• Band/Heft Quelle: 11(2022), 14, Artikel-ID 3934, Seite 1-11
• ISSN Quelle: 2077-0383
• DOI: doi:10.3390/jcm11143934
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: aorta
• Sach-SW: aortic surgery
• Sach-SW: gene therapy
• Sach-SW: marfan syndrome
• Sach-SW: TGF-β
• Sach-SW: translational therapy
• K10plus-PPN: 1815779896
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Marfan syndrome (MFS) is one of the most common inherited disorders of connective tissue caused by mutations of the fibrillin-1 gene (FBN1). Vascular abnormalities, such as the enlargement of the aorta with the risk of life-threatening rupture are frequently observed. However, current treatment is limited and therapeutic options focus solely on symptomatic therapy. Gene therapy focuses on genetically modifying cells to produce a therapeutic effect and may be a promising treatment option for MFS. Here, we first provide an overview of the historical background and characterization of MFS. Subsequently, we summarise current gene therapy options and possible translational concepts for this inherited disorder that affects connective tissue.